At the recently concluded American Society of Clinical Oncology meeting, Gilead Sciences, Inc. and Arcus Biosciences, Inc. joined the ranks of firms developing combinations of PD-1 and PD-L1 inhibitors with monoclonal antibodies targeting TIGIT that have not yet lived up to everyone’s expectations in lung cancer.
Lung cancer specialists, meanwhile, hope to see more in the way of biomarkers that might lead to better efficacy for...








